Biotechnology company Roche (SIX: RO, ROG) (OTCQX: RHHBY) announced on Monday that it has expanded its digital pathology open environment by integrating over 20 new artificial intelligence (AI) algorithms from eight new collaborators. These partnerships aim to support pathologists and scientists in advancing cancer research and diagnosis, enhancing precision medicine through targeted treatments.
This integration is facilitated through Roche's navify Digital Pathology software, which now offers a wider range of AI tools to improve pathology insights.
Collaborators include Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics and Stratipath, each contributing specialised algorithms for various cancer types such as prostate, breast, lung and colorectal cancers.
Roche, a leader in digital pathology solutions, continues its commitment to personalised healthcare by incorporating innovative AI-driven diagnostics into routine clinical practice.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment